rs104893665
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PP3_ModeratePP5_Very_Strong
The NM_003124.5(SPR):c.448A>G(p.Arg150Gly) variant causes a missense change. The variant allele was found at a frequency of 0.0000855 in 1,613,918 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000059 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000088 ( 0 hom. )
Consequence
SPR
NM_003124.5 missense
NM_003124.5 missense
Scores
4
10
5
Clinical Significance
Conservation
PhyloP100: 3.95
Genes affected
SPR (HGNC:11257): (sepiapterin reductase) This gene encodes an aldo-keto reductase that catalyzes the NADPH-dependent reduction of pteridine derivatives and is important in the biosynthesis of tetrahydrobiopterin (BH4). Mutations in this gene result in DOPA-responsive dystonia due to sepiaterin reductase deficiency. A pseudogene has been identified on chromosome 1. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.892
PP5
Variant 2-72888457-A-G is Pathogenic according to our data. Variant chr2-72888457-A-G is described in ClinVar as [Pathogenic]. Clinvar id is 12941.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SPR | NM_003124.5 | c.448A>G | p.Arg150Gly | missense_variant | 2/3 | ENST00000234454.6 | NP_003115.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SPR | ENST00000234454.6 | c.448A>G | p.Arg150Gly | missense_variant | 2/3 | 1 | NM_003124.5 | ENSP00000234454.5 | ||
SPR | ENST00000498749.1 | n.393A>G | non_coding_transcript_exon_variant | 2/3 | 3 | ENSP00000519026.1 |
Frequencies
GnomAD3 genomes AF: 0.0000591 AC: 9AN: 152194Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
9
AN:
152194
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000557 AC: 14AN: 251238Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135754
GnomAD3 exomes
AF:
AC:
14
AN:
251238
Hom.:
AF XY:
AC XY:
3
AN XY:
135754
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000883 AC: 129AN: 1461724Hom.: 0 Cov.: 31 AF XY: 0.0000839 AC XY: 61AN XY: 727138
GnomAD4 exome
AF:
AC:
129
AN:
1461724
Hom.:
Cov.:
31
AF XY:
AC XY:
61
AN XY:
727138
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000591 AC: 9AN: 152194Hom.: 0 Cov.: 33 AF XY: 0.00 AC XY: 0AN XY: 74362
GnomAD4 genome
AF:
AC:
9
AN:
152194
Hom.:
Cov.:
33
AF XY:
AC XY:
0
AN XY:
74362
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
7
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Dopa-responsive dystonia due to sepiapterin reductase deficiency Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Genetics, Royal Melbourne Hospital | Aug 04, 2022 | This sequence change in SPR is predicted to replace arginine with glycine at codon 150, p.(Arg150Gly). The arginine residue is highly conserved (100 vertebrates, UCSC), and is located in a beta-strand. There is a large physicochemical difference between arginine and glycine. The highest population minor allele frequency in gnomAD v2.1 is 0.02% (7/35,402 alleles) in the Latino/admixed American population, which is consistent with a recessive condition. This variant has been detected in at least ten individuals with sepiapterin reductase deficiency. Of those individuals, two individuals were homozygous and 8 were compound heterozygous for the variant and a pathogenic or likely pathogenic variant and one of those was confirmed in trans by parental testing (PMID: 11443547, 17159114, 19491146, 22522443). The variant demonstrates deficient enzyme activity in an in vitro functional assay (PMID: 11443547). Multiple lines of computational evidence predict a deleterious effect for the missense substitution (5/6 algorithms). Based on the classification scheme RMH Modified ACMG Guidelines v1.5.1, this variant is classified as PATHOGENIC. Following criteria are met: PM3_VeryStrong, PS3_Supporting, PM2_Supporting, PP3. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 12, 2006 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 15, 2019 | Variant summary: SPR c.448A>G (p.Arg150Gly) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.6e-05 in 251238 control chromosomes (gnomAD). The variant, c.448A>G, has been reported in the literature in multiple homozygous- and compound heterozygous individuals affected with Sepiapterin reductase deficiency (e.g. Bonafe_2001, Clot_2009, Friedman_2012). These data indicate that the variant is very likely to be associated with disease. At least one publication, Bonafe_2001, reported that the variant almost completely abolished the enzyme activity. Three ClinVar submitters (evaluation after 2014) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jan 27, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jan 05, 2022 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | May 11, 2023 | Published functional studies demonstrate absent sepiapterin reductase enzyme activity in vitro (Bonafe et al., 2001); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 24212389, 16917893, 19491146, 28516087, 21677200, 11443547, 17159114, 27080360, 26123188, 23430877, 22522443, 21431957, 33977029, 30799092, 31589614) - |
SPR-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 21, 2023 | The SPR c.448A>G variant is predicted to result in the amino acid substitution p.Arg150Gly. This variant has been reported to be causative for dopa-responsive dystonia due to sepiapterin reductase deficiency (Bonafé et al. 2001. PubMed ID: 11443547; Leuzzi et al. 2013. PubMed ID: 24212389; Thibert et al. 2012. PubMed ID: 23430877). This variant is reported in 0.020% of alleles in individuals of Latino descent in gnomAD. This variant is interpreted as pathogenic. - |
Dystonic disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jul 25, 2022 | This sequence change replaces arginine, which is basic and polar, with glycine, which is neutral and non-polar, at codon 150 of the SPR protein (p.Arg150Gly). This variant is present in population databases (rs104893665, gnomAD 0.02%). This missense change has been observed in individual(s) with sepiapterin reductase deficiency (PMID: 11443547, 21431957, 21677200, 23430877, 24212389). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 12941). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects SPR function (PMID: 11443547). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D
MetaSVM
Uncertain
T
MutationAssessor
Benign
N
PrimateAI
Benign
T
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Uncertain
D
Sift4G
Uncertain
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at